Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | ELOC | Q15369 | 1/20 | 0.37 |
| ▸ | ELOB | Q15370 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6340500 | 0.90 | SIRT2 (0.36) | SIRT2CES1VHLELOCELOB | |
| SCHEMBL11352770 | 0.82 | SIRT2 (0.43) | SIRT2MAOBMAOAKMT2ALMNA | |
| SCHEMBL67615 | 0.82 | MEN1 (0.46) | SIRT2CES1MAOBMAOAVHL | |
| SCHEMBL30543406 | 0.82 | MEN1 (0.46) | SIRT2CES1MAOBMAOAVHL | |
| SCHEMBL12316746 | 0.79 | MAOB (0.44) | SIRT2MAOBMAOAVHLELOC | |
| SCHEMBL8191575 | 0.79 | MAOB (0.37) | SIRT2MAOBMAOAVHLELOC | |
| SCHEMBL12316699 | 0.79 | LMNA (0.42) | SIRT2MAOBMAOAVHLELOC | |
| SCHEMBL14053377 | 0.79 | NOTUM (0.42) | SIRT2MAOBMAOAVHLELOC | |
| SCHEMBL31424317 | 0.79 | MAOB (0.40) | SIRT2MAOBMAOALMNAMAPT | |
| SCHEMBL12316580 | 0.79 | SIRT2 (0.47) | SIRT2MAOBMAOAVHLELOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012140-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-6576657-B2 | Nitrogen containing heterocyclic compounds useful as anticoagulants | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-21 | — | — | US | disclosed |
| US-6265397-B1 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1012140-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | SIRT2 3161/4885CES1 122/4885MAOB 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.